Comparative Pharmacology
Head-to-head clinical analysis: TECENTRIQ versus TECENTRIQ HYBREZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TECENTRIQ versus TECENTRIQ HYBREZA.
TECENTRIQ vs TECENTRIQ HYBREZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atezolizumab is a humanized monoclonal IgG1 antibody that binds to PD-L1, blocking its interaction with PD-1 and CD80 receptors, thereby reversing PD-L1-mediated inhibition of T-cell activation and restoring anti-tumor immune responses.
Programmed death-ligand 1 (PD-L1) blocking antibody that binds to PD-L1, preventing interaction with PD-1 and B7.1, thereby reactivating antitumor immune responses.
800 mg intravenously every 2 weeks; or 1200 mg intravenously every 3 weeks; or 1680 mg intravenously every 4 weeks.
840 mg intravenously every 2 weeks, or 1200 mg intravenously every 3 weeks, or 1680 mg intravenously every 4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 27 days (range: 20–35 days). This long half-life supports every-3-week dosing and reflects slow clearance typical of IgG1 antibodies.
Terminal elimination half-life is approximately 6.5 days (range 4–9 days), supporting a subcutaneous dosing interval of every 3 weeks.
Tecentriq (atezolizumab) is a monoclonal antibody; elimination occurs via intracellular catabolism into amino acids. No renal or biliary/fecal excretion of intact drug. 0% unchanged in urine or feces.
Almost entirely renal as unchanged drug (approximately 90% of a subcutaneously administered dose is eliminated via the kidneys within 96 hours). Biliary/fecal elimination accounts for less than 1%.
Category C
Category C
Antineoplastic, PD-L1 Inhibitor
Antineoplastic, PD-L1 Inhibitor